Cannabix Technologies Inc. develops marijuana and alcohol breathalyzer technologies for law enforcement, workplaces, and laboratories in the United States. It offers Cannabix Marijuana Breath Test (MBT) system for tetrahydrocannabinol (THC) detection and quantification, which includes the Cannabix Breath Collection Unit (BCU) and Breath Cartridge (BC) for non-invasive, portable, standardized human breath sample collection, storage, and transportation. The company also provides BreathLogix, an autonomous alcohol screening system for rapid and repeatable high-volume screening in various employment settings. In addition, the company develops other TCH-detecting technologies, including mass spectrometer breath sampler (MSBS) technology, as well as high-field asymmetric waveform ion mobility spectrometry (FAIMS) and FAIMS-mass spectrometer systems. It has a strategic partnership and development agreement with Omega Laboratories Inc. for the development and commercialization of MBT technology. The company was formerly known as West Point Resources Inc. and changed its name to Cannabix Technologies Inc. in August 2014. Cannabix Technologies Inc. was incorporated in 2011 and is based in Burnaby, Canada.…
Cannabix Technologies to Present Multi-Drug Breath Technology at BC Centre for Excellence on Substance Use Disorders
Cannabix Technologies (CNSX: BLO) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Medical Devices industry, part of the Healthcare sector.
The shares were at 0.3500 CAD on 20 November 2026, down 41.7% over 52 weeks. Its 52-week range is 0.2900 CAD to 0.9500 CAD: the price is 63.2% below the high and 20.7% above the low.
Its market capitalisation is 43.11M CAD.
Cannabix Technologies reports return on equity of -323.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 1.01M CAD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.
No upcoming events tracked.